- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer | Clinical
FDA Grants Regular Approval to Capmatinib for Patients With METex14-Positive NSCLC
August 11, 2022
An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.
Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLC
August 09, 2022
The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.
Promising ORR Rates Seen With Sotorasib Plus SHP2 Inhibition in KRAS G12C–Mutated NSCLC
August 07, 2022
Sotorasib and RMC-4630 elicited promising preliminary activity in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer.
Robust Efficacy Achieved With Tepotinib in METex14-Altered NSCLC
August 07, 2022
Tepotinib achieved robust efficacy in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations, according to a primary analysis of cohort C of the phase 2 VISION trial.
Sitravatinib Plus Tislelizumab Elicits Antitumor Activity in PD-L1+ Advanced NSCLC
August 07, 2022
Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.
Promising Safety With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLC
August 07, 2022
Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.
GDC-6036 Monotherapy Reveals Promising Activity in KRAS G12C–Mutant NSCLC
August 07, 2022
A phase 1a trial of GDC-6036 showed encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.
Ociperlimab/Tislelizumab Combo Elicits Antitumor Activity in PD-L1+ NSCLC
August 06, 2022
Ociperlimab plus tislelizumab revealed promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer.
Triplet Combo Conveys Survival Benefit in PD-L1-Positive mNSCLC
August 06, 2022
Tremelimumab plus durvalumab and chemotherapy displayed improvements in clinical and survival benefit in patients with PD-L1 negative metastatic non–small cell lung cancer.
Larotrectinib Shows Continued Efficacy in NTRK-Positive Lung Cancer
August 06, 2022
Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.